- recruitingTherapeutic exploratory (Phase II)
(22551) A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has reached the primary completion endpoint, or main data analysis, or has been stopped prematurely.
This study is for adults with solid cancer tumours who previously took part in an earlier trial using regorafenib. It allows people to continue receiving this targeted cancer medication safely while doctors closely monitor any side effects and see if doses need to be changed over time.
Spain · France - recruitingTherapeutic confirmatory (Phase III)
A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered as a Single Agent or in Combination with other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study
This study is for adults with solid cancer tumours who previously took part in an earlier trial of a medicine called pertuzumab. It allows them to keep receiving pertuzumab, either alone or with other cancer drugs, while doctors carefully check for any side effects and see how their cancer responds.
Portugal · Italy · Spain